Incyte announced the positive review results from the pivotal study TRuE-AD3, randomized, vehicle-controlled, evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children ( ages 2 to < 12 years old) with atopic dermatitis. The study met the primary endpoint and showed more patients treated with ruxolitinib cream 0.75% […]
Hitesh
Cotiviti Introduces Prepay Claim Review Solution for Coordination of Benefits (COB) Validation
Cotiviti, a leader in data-driven healthcare solutions, is expanding its end-to-end Coordination of Interest (COB) solution by adding the potential COB authentication capabilities. This comprehensive service allows health plans to reduce overpayments by reviewing claims and determining payment liability after arbitration but before payment, making it the ultimate service provider. […]
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Sensorion, a pioneering clinical-stage biotech company dedicated to the development of new therapies to restore, treat, and prevent hearing loss disorders, today announced that it has submitted an Application Initial clinical trial (CTA) for OTOF-GT for the UK Medicines and Health Agency. The Healthcare Products Regulatory Authority (MHRA). The Phase […]
BrainTale Has Presented at the European Academy of Neurology and the World Parkinson Congress the Interest of Its Digital Biomarker Platform for the Early and Differential Diagnosis of Parkinson’s Disease
BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, presented preliminary results during the European Academy of Neurology (Budapest, July 1 – 4, 2023) and the World Parkinson congress (Barcelona, July 4 – 7, 2023) demonstrating the interest of its digital […]
IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award
IQVIA, one of the world’s leading providers of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced an initiative to support the league, along with the National Basketball Association and partners at Harvard University, Columbia University and the Bioreference Institute. announced that it was […]
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Amneal Pharmaceuticals, Inc. announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with […]
Acadia Healthcare Forms Joint Venture Partnership with SolutionHealth in New Hampshire
Healthcare company Acadia, Inc. announced that it has formed a joint venture with SolutionHealth to build a state-of-the-art, 144-bed behavioral health hospital in southeastern New Hampshire to address growing and unmet need. for accessible, high-quality behavioral health services in the state. This partnership expands Acadia’s acute services reach to a new […]
Bright Health Group Enters into Definitive Agreement with Molina Healthcare to Sell its California Medicare Advantage Business, Bolstering Capital Position to Continue Advancing its Value-Driven Care Model
Bright Health Group, Inc., the value-driven, technology-driven healthcare company, today announced that it has entered into a definitive agreement with Molina Healthcare, Inc. (“Molina”), for the sale of California Medicare Advantage, Brand New Day and the Central Health Plan business, for a total purchase price of $600 million. At the […]
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Aldeyra Therapeutics, Inc., a biotechnology company dedicated to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced overall positive results from Phase 2 clinical trial of ADX Intravitreal -2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa. Compared to baseline, the clinical trial […]
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS, for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb announces that the European Commission has approved CAMZYOS® for the treatment of symptomatic hypertrophic obstructive cardiomyopathy in adult patients. CAMZYOS is the first and only reversible and allotropic Selective Cardiac Myosin Inhibitor approved in all Member States of the European Union* and the first Cardiac Myosin Inhibitor […]
